What’s even crazier Chaka is that ARL* ran up to .15 from .0011 in September 2017 even with an increase in the AS from 2 billion to 10 billion (w/ OS of 9,420,999,800) that was filed in January 2017 and the company openly saying in September 2017 that it did not have the resources at the time to become SEC current. Apparently, that same month the company received FDA clearance for some insulin dosage feature related to one of its technologies. My takeaway from doing a little bit of research on that ticker is that while SEC compliance status and SS is important, each does not automatically eliminate a ticker’s chance for a monumental breakout. I will add though that the pps did not stay at .15 long at all for obvious reasons. But LAHO/GSCG appear to be in much better off positions than that ticker. I’m very optimistic about our potential in the coming weeks. Gonna be a great holiday season for all of us. Cheers.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.